Financial Security Advisor Inc. Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Financial Security Advisor Inc. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,779 shares of the medical research company’s stock, valued at approximately $206,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Abacus Planning Group Inc. raised its position in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after acquiring an additional 140 shares in the last quarter. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Pegasus Asset Management Inc. grew its stake in shares of Edwards Lifesciences by 0.4% during the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after purchasing an additional 159 shares during the period. Mount Yale Investment Advisors LLC increased its holdings in shares of Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after purchasing an additional 162 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $71.42 on Friday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a 50 day moving average price of $72.71 and a 200 day moving average price of $70.20. The company has a market cap of $42.12 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,489 shares of company stock valued at $2,002,829. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.